Oral BBR (100, 200 mg/kg) increases the amount of dopamine secretion in the brain to improve Parkinson’s disease (PD) symptoms by enhancing tyrosine hydroxylase activity in Enterococcus and promoting levodopa production in the intestine of a PD mouse model (71). Here, TH is linked to Parkinson disease.